Vonoprazan Provides Foundation For Newly Minted Phathom

 
• By Ian Haydock

Newly formed US venture Phathom, with industry veteran Tachi Yamada on board, has picked up selected rights to P-CAB molecule as Takeda continues to shed non-core assets and rights.

3d render illustration of human digestive system - front view
Phathom Looks To Build GI Business • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas